Muscle and Longevity: Sarcopenia, Strength and the Difference Between Correlation and Cause

Executive summary

• Muscle mass, and more importantly muscle strength, are repeatedly associated with lower death rates and better health in later life. That is an association. No study has shown, or realistically could show, that building muscle causes a longer life (Ref 2, Ref 3).

• Sarcopenia, the gradual loss of muscle with age, tracks with disability and higher mortality (Ref 1, Ref 2). The direction of cause is genuinely uncertain: illness and inactivity waste muscle, just as lost muscle may worsen the course of illness.

• Grip strength, and the ability to lower yourself to the floor and stand back up without using your hands, are useful markers of overall robustness (Ref 3, Ref 4, Ref 5). I treat them as a dashboard warning light, not the engine, and I do not train them for their own sake.

• Skeletal muscle is the body's largest site for clearing dietary glucose and a major place where fuel is oxidised (Ref 7, Ref 8). More working muscle may put you in a better position to handle carbohydrate, which is not the same as preventing diabetes.

• Muscle behaves as a secretory organ, releasing signalling molecules called myokines (Ref 9). That is real biology. The onward leap to "muscle prevents dementia" is one I am not willing to make.

• Resistance training is associated with lower mortality and, in my view, is worth doing (Ref 13). I favour training for strength and quality of movement rather than size for its own sake.

• Very large physiques, especially those built with anabolic steroids, carry a measurable cardiovascular cost (Ref 12). That is much of the answer to why some of the most muscular people still die young.

• I declare my interests plainly. I am a former competitive powerlifter, so I am naturally inclined to value this kind of training, and I sell no product mentioned anywhere in this article.

Introduction

"Muscle is longevity" has become one of those phrases that gets repeated until it sounds like a settled fact. It is not, and the honest version is more interesting than the slogan. There is a real and reasonably consistent signal in the data linking muscle, and particularly strength, to a longer and healthier life. There is also a hard limit on what that signal can prove. I want to walk through both.

I should be clear at the outset about what I am and am not claiming, because this is a subject that invites overstatement in both directions. I am not claiming that adding muscle is proven to extend your life; the studies cannot carry that weight, and I will explain why. I am also not dismissing muscle as a vanity pursuit; the association with health is genuine and, mechanistically, quite plausible. The narrower and more defensible position is this: muscle mass and strength are correlated with health and survival, building and keeping muscle is a sensible thing to do for reasons I find persuasive, but "correlated with" is not "the cause of," and the distinction matters enormously once you start deciding what to actually do with your training.

By way of background, and so my biases are visible: I trained first in dentistry, then in dermatology, and separately in anti-aging medicine and in metabolic medicine, and I hold a qualification in sports nutrition. Before medicine I competed for years as a powerlifter, at times training alongside some of the best-known lifters in the sport, including Andy Bolton, the first man to deadlift over 1,000 pounds, and I still work with athletes across a range of levels, including retired ones. That background is useful experience and it is also a bias, and I would rather you saw it than have to guess at it.

There is a question sitting underneath the whole topic, and it is worth stating in its blunt form. Does muscle make you live longer, or does muscle simply travel in the company of people who were going to live longer anyway? Hold that question in mind, because most of what follows is an attempt to answer it honestly rather than conveniently.

What sarcopenia is, and what the mortality data can say

Sarcopenia is the medical term for the age-related loss of muscle mass and strength. The current European consensus definition now places low muscle strength, rather than low muscle mass alone, at the front of the diagnosis, which is itself telling: strength, not size, is what best flags the problem (Ref 1). I am deliberately not going to quote you a headline figure for how much muscle we supposedly lose each year, because those numbers are usually extrapolated from one studied group onto the whole of humanity, and I do not think that kind of variable travels well between populations. That we tend to carry less muscle in old age than in youth is not in dispute; the precise arithmetic is less trustworthy than it looks.

What the literature does show, fairly consistently, is that people with sarcopenia have higher death rates than those without. A systematic review and meta-analysis of older nursing-home residents, for example, found sarcopenia to be a predictor of all-cause mortality (Ref 2). Set alongside the strength data below, the association is not subtle.

Here is the necessary caution, and it is the whole argument of this article in miniature. This is observational, and the arrow of cause can point either way. Losing muscle may worsen your health; equally, being ill, frail, inactive or undernourished wastes muscle, so low muscle can be a consequence of poor health rather than its cause. In all likelihood both run at once, feeding each other. A study of this kind can establish that muscle and survival move together. It cannot, on its own, tell you that putting muscle on a sick person turns them into a well one.

I will give one clinical memory, offered as illustration and not as evidence. Standing in for a senior house officer in the emergency department at North Manchester General Hospital, I saw two elderly patients arrive after similar falls. One walked away with a bruise. The other sustained multiple fractures and spent weeks in hospital. The one who walked away had, in effect, bought themselves what I think of as biological insurance and a biological pension: a body robust enough to absorb an accident that flattened someone else. That is what "longevity muscle" means to me. It is not a physique. It is a reserve.

Grip strength and getting off the floor: markers, not levers

Two measures come up again and again in this field. The first is grip strength. In a prospective study of roughly half a million people in the UK Biobank, lower grip strength was associated with higher all-cause mortality and with cardiovascular disease, respiratory disease and cancer (Ref 3). A dose-response meta-analysis has since mapped how the risk changes across the range of handgrip values (Ref 4). The second is the ability to sit down onto the floor and rise again without pushing off with a hand or knee, sometimes called the sitting-rising test; scoring poorly on it has been associated with higher all-cause mortality (Ref 5). There is also evidence that a strength measure predicts poor physical performance better than a measure of muscle mass does (Ref 6), which fits the shift in the sarcopenia definition I mentioned above.

I find these genuinely useful as markers. What I do not do is treat them as levers. I do not train my grip, or practise getting off the floor, under the specific belief that doing so will extend my life. My reasoning is the one running through this whole piece: grip strength is a proxy for something larger, namely overall strength, muscle quality, coordination and body composition. Think of it as the warning light on a car dashboard. The light tracks the state of the engine reliably, but unscrewing the bulb does not fix the engine, and polishing the light does not make the car run better. If my grip improves as a by-product of getting generally stronger, good. Chasing the marker itself, in the hope the outcome follows, is to mistake the light for the engine. I hold that view provisionally, and I am open to where the exceptions might lie.

Muscle and blood sugar: a reservoir for glucose

Across my clinical career I noticed, as a personal observation and emphatically not as a formal statistic, that patients carrying more muscle seemed less commonly diabetic. An impression from one clinician's practice describes nothing about the world at large, so treat it as a prompt for the mechanism rather than a finding.

The mechanism is reasonably well understood. Skeletal muscle is the principal site at which the body disposes of glucose from the bloodstream under the influence of insulin (Ref 8). Muscle also stores glucose as glycogen, so a larger, well-trained muscle mass acts as a bigger reservoir into which dietary glucose can be parked. Picture a sponge: a bigger, healthier sponge soaks up a spill faster and holds more of it. And because muscle is dense with mitochondria, the small structures that oxidise fuel (that is, chemically strip electrons from fuel molecules to release usable chemical fuel in the form of ATP), it also provides more of the engines needed to actually use what it takes up. Consistent with this, higher relative muscle mass has been associated, in a large cross-sectional analysis, with better insulin sensitivity and a lower prevalence of pre-diabetes (Ref 7).

Two honest caveats. First, the human muscle-mass data here are cross-sectional, a single snapshot in time, so once again they show association rather than proof of cause. Second, none of this means muscle "prevents" diabetes. What it means is that a more muscular, more active body may be in a better position to clear glucose when you eat carbohydrate. It puts you in a stronger position; it does not issue a guarantee, and how much it helps any particular person depends on their circumstances, which I cannot assess through a screen.

It is worth adding a note that often causes confusion. In someone eating very few carbohydrates, muscle can deliberately down-regulate how much glucose it lets in when insulin signals, in order to spare glucose for the tissues that most rely on it. This is a normal adaptation, best called physiological insulin resistance, and it is not the same thing as the pathological insulin resistance of metabolic disease, even though a single fasting blood test can look superficially similar. Reading the one without the other in mind is a common way to frighten a healthy low-carbohydrate eater unnecessarily.

Muscle as a gland: myokines and the brain

Contracting muscle releases signalling molecules, collectively called myokines, into the circulation; in this sense muscle behaves not just as a motor but as a secretory organ, effectively a gland (Ref 9). Some of these molecules have anti-inflammatory actions, and the biology is real and interesting. The everyday version is that a working muscle posts chemical messages to the rest of the body, and some of those messages reach the brain.

From here the popular story runs straight to "so building muscle wards off dementia," and this is where I get off. There are associations in that direction: lower grip strength has been linked with cognitive decline (Ref 10), and low grip strength appears among the risk factors identified for young-onset dementia in large datasets (Ref 11). But grip strength in these studies is doing its usual job as a marker of general health, and the people with more of it differ in many other ways, from activity levels to overall disease burden, that also affect the brain. Reading these associations as "muscle protects the brain" runs well ahead of what the study design can support. My own position is that dementia is multifactorial, that muscle is at most one strand among many, and that I would not offer muscle-building as a cognitive insurance policy. That muscle secretes bioactive molecules is not in question; what those molecules do for the aging human brain, in the doses a normal training life produces, is something I am genuinely still collecting data on.

Why the muscular can still die young: size, drugs and the heart

This is the part that punctures the slogan, and it needs saying plainly. If muscle straightforwardly caused longevity, the most muscular people would be the longest-lived, and they are not. Some visibly powerful physiques belong to people who die early. Two things reconcile that with everything above.

The first is that muscle mass is correlated with health, not a direct cause of it, so a large physique is not automatically a healthy one. The second is more specific: a good deal of extreme size is built with anabolic-androgenic steroids, and those drugs carry a real cardiovascular cost. In a cross-sectional study of long-term male weightlifters, those with years of steroid use showed reduced heart pump function and higher volumes of coronary artery plaque than non-users, with the plaque burden tracking the cumulative lifetime dose (Ref 12). Anabolic steroids also tend to lower HDL and raise LDL, the lipoprotein particle that carries cholesterol through the blood, shifting the whole picture in an unfavourable direction.

The caveats apply here too, and I will not pretend otherwise: this is cross-sectional, and men who use steroids differ from those who do not in ways beyond the drugs. But the dose-response relationship with coronary plaque is exactly the kind of internal consistency that makes me take the signal seriously rather than wave it away. This is the sharp end of the vanity-versus-longevity distinction. Size pursued for appearance, and chemically forced past what the body would build on its own, is close to the opposite of what I mean by longevity muscle. My own view, held firmly, is to avoid performance-enhancing drugs wherever you possibly can.

What training for longevity muscle looks like, in practice

Before any specifics, the honest framing. Resistance training is associated with lower all-cause mortality in systematic review and meta-analysis (Ref 13). That association is, predictably, observational and subject to the healthy-user problem: people who lift weights tend to differ from people who do not in diet, income, sleep and much else. I still think the case for doing it is strong, because the mechanistic story and the associations point the same way, but I want you to see that I am reasoning from convergent plausibility, not from proof.

High-intensity interval work earns a specific mention. Brief, hard intervals drive the same molecular machinery that builds mitochondria and raises the muscle's capacity to oxidise both glucose and fat (Ref 14). I favour that over long, steady, monotonous cardiovascular sessions, both for what it does inside the muscle and for the heart.

What follows is my own approach, and a starting point for discussion, not a prescription for you specifically. I cannot see you through a screen, and the right programme depends on your history, your joints and your circumstances.

• Take the working weight to genuine muscular failure at roughly eight repetitions, for up to two sets. Quality over quantity.

• Never train two days in a row, and only train again once you have recovered from the previous session. Adaptation happens during recovery, the way plaster sets between coats, not during the session itself.

• Alternate the emphasis through the year, spending a couple of months oriented toward size and then a couple oriented toward strength, and back again.

• Prioritise form over the number on the bar. The load is a means, not the goal.

• If you develop any niggle in a joint or soft tissue, have it looked at early by a good local clinician or physiotherapist rather than training through it. Preserving mobility over decades is worth more than any single session, and this is exactly where an ongoing relationship with a clinician who knows you earns its keep.

• Avoid performance-enhancing drugs. I lifted for years mostly for strength rather than size (my own best deadlift was over 250 kg at a bodyweight around 72 kg), which I think, though I hold it as an opinion, is the more health-favourable emphasis of the two. Training to the level I once did is not itself healthy, given what it asks of the body; done at a sensible level it is, in my view, entirely reasonable. I still train alongside sports such as cricket and football, and I make no claim that my particular mix is optimal for anyone else. On the finer question of exactly how much volume is ideal, the field genuinely disagrees, and I am still collecting data rather than pretending to a certainty I do not have.

Feeding muscle: protein, and the low-carbohydrate question

You cannot build or defend muscle without the raw materials, and the raw material is protein, specifically the essential amino acids and above all leucine, which acts as a trigger for muscle protein synthesis. Higher-quality, more complete proteins do this job better, and the protein quality that matters most for muscle comes from complete animal sources: meat, fish, eggs and dairy supply the full complement of essential amino acids in the right proportions and in a highly usable form (Ref 15). Interventions that supply leucine-rich protein have been shown to improve measures of muscle in older adults at risk of sarcopenia (Ref 16). If I had to name a single dietary lever for muscle, it would be sufficient complete animal-source protein, not a shelf of supplements.

The more contested question is the metabolic state you train in. I lean toward a low-carbohydrate approach, and toward training in a fat-adapted, sometimes ketogenic state. Recent work from Professor Tim Noakes and colleagues describes how a low-carbohydrate, high-fat pattern shifts the body toward oxidising fat at higher exercise intensities (Ref 17). A 2026 review by the same group, drawing on more than a hundred years of evidence, goes further: it reports that fat-adapted athletes achieve exceptional rates of fat oxidation and equivalent performance despite low carbohydrate intake, and argues that carbohydrate is not an obligatory fuel for exercise (Ref 20). That is mechanistically the direction I find compelling, though I hold it as a lean rather than a settled verdict.

Honesty requires me to place the counter-evidence next to my own lean, not to hide it. Controlled work by Louise Burke and colleagues found that adapting to a low-carbohydrate, high-fat diet, while it did raise fat oxidation, impaired exercise economy and performance in elite endurance athletes despite adequate glycogen (Ref 18). A randomised crossover trial reported reduced anaerobic, high-intensity performance on a ketogenic diet (Ref 19). These are real results and I will not explain them away. What I will say is that some of the apparent impairment may reflect too short an adaptation period and large differences between individuals, that the field is genuinely unsettled, and that I am not claiming carbohydrate is required either to perform or to build muscle. My position is a lean, grounded in the biochemistry, not a settled verdict, and it is one of the places I am still actively collecting data. Where the evidence pulls against me, I would rather show you than bury it.

Conclusion

Muscle is worth building and worth keeping. I believe that, I train on it, and I would say the same to almost anyone who asked. But the reasons are quieter and more honest than the slogan suggests. Muscle, and especially strength, is consistently associated with a longer and more capable life; the mechanisms, from glucose handling to the myokines a working muscle secretes, are plausible; and resistance training sits alongside those associations rather than against them. What none of it establishes is direct cause. No study can, because you cannot follow a person from birth to death while holding every other variable still, and so the honest ceiling on this entire field is correlation, not proof. That some of the most muscular people die young, and that some of the longest-lived people were never notably muscular, should keep us humble about how much of the story muscle really tells.

What I take from that is not defeatist but practical. Build a body that is strong, that moves well, that can absorb an accident and clear a meal, and treat the pursuit of size for its own sake, particularly when it is drug-assisted, as a different project altogether from the pursuit of a long and healthy life. Beyond that, the best any of us can do is understand the underlying biochemistry, physiology and anatomy and make sensible decisions on top of them, adjusted for the person we actually are. I cannot make those adjustments for you through a screen, and I would be wary of anyone who claimed they could.

Disclosures

I have no commercial interest in, and I am not selling, any supplement, device or product mentioned in this article; the recommendations here cost nothing. I should also declare a relevant bias: I am a former competitive powerlifter and a long-term advocate of resistance training, which naturally disposes me to value it, and I have tried to flag throughout the places where my own lean runs ahead of the evidence. I offer private consultations for people who want to talk their own situation through, but I will put it plainly: for most people, a good, regular relationship with a local clinician who can actually examine you is worth more than a single consultation with me.

References

Identified and verified via PubMed; DOI links included.

1. Cruz-Jentoft et al. Sarcopenia: revised European consensus on definition and diagnosis. Age and Ageing, 2019. https://doi.org/10.1093/ageing/afy169

2. Zhang et al. Sarcopenia as a predictor of all-cause mortality among older nursing home residents: a systematic review and meta-analysis. BMJ Open, 2018. https://doi.org/10.1136/bmjopen-2017-021252

3. Celis-Morales et al. Associations of grip strength with cardiovascular, respiratory, and cancer outcomes and all-cause mortality: prospective cohort study of half a million UK Biobank participants. BMJ, 2018. https://doi.org/10.1136/bmj.k1651

4. López-Bueno et al. Thresholds of handgrip strength for all-cause, cancer, and cardiovascular mortality: a systematic review with dose-response meta-analysis. Ageing Research Reviews, 2022. https://doi.org/10.1016/j.arr.2022.101778

5. Brito et al. (incl. Araújo CGS). Ability to sit and rise from the floor as a predictor of all-cause mortality. European Journal of Preventive Cardiology, 2014. https://doi.org/10.1177/2047487312471759

6. Kim et al. Muscle strength: a better index of low physical performance than muscle mass in older adults. Geriatrics & Gerontology International, 2016. https://doi.org/10.1111/ggi.12514

7. Srikanthan P, Karlamangla AS. Relative muscle mass is inversely associated with insulin resistance and prediabetes: findings from NHANES III. Journal of Clinical Endocrinology & Metabolism, 2011. https://doi.org/10.1210/jc.2011-0435

8. Mastrototaro L, Roden M. Insulin resistance and insulin sensitizing agents. Metabolism, 2021. https://doi.org/10.1016/j.metabol.2021.154892

9. Pedersen BK, Febbraio MA. Muscles, exercise and obesity: skeletal muscle as a secretory organ. Nature Reviews Endocrinology, 2012. https://doi.org/10.1038/nrendo.2012.49

10. Alfaro-Acha et al. Handgrip strength and cognitive decline in older Mexican Americans. Journals of Gerontology Series A, 2006. https://doi.org/10.1093/gerona/61.8.859

11. Hendriks et al. Risk factors for young-onset dementia in the UK Biobank. JAMA Neurology, 2024. https://doi.org/10.1001/jamaneurol.2023.4929

12. Baggish et al. Cardiovascular toxicity of illicit anabolic-androgenic steroid use. Circulation, 2017. https://doi.org/10.1161/CIRCULATIONAHA.116.026945

13. Shailendra et al. Resistance training and mortality risk: a systematic review and meta-analysis. American Journal of Preventive Medicine, 2022. https://doi.org/10.1016/j.amepre.2022.03.020

14. Gibala MJ. Molecular responses to high-intensity interval exercise. Applied Physiology, Nutrition, and Metabolism, 2009. https://doi.org/10.1139/H09-046

15. Paddon-Jones D, Rasmussen BB. Dietary protein recommendations and the prevention of sarcopenia. Current Opinion in Clinical Nutrition and Metabolic Care, 2009. https://doi.org/10.1097/MCO.0b013e32831cef8b

16. Bauer et al. Effects of a vitamin D and leucine-enriched whey protein nutritional supplement on measures of sarcopenia in older adults (the PROVIDE study): a randomized, double-blind, placebo-controlled trial. Journal of the American Medical Directors Association, 2015. https://doi.org/10.1016/j.jamda.2015.05.021

17. Noakes TD, Prins PJ, Volek JS, et al. Low carbohydrate high fat ketogenic diets on the exercise crossover point and glucose homeostasis. Frontiers in Physiology, 2023. https://doi.org/10.3389/fphys.2023.1150265

18. Burke et al. Adaptation to a low carbohydrate high fat diet is rapid but impairs endurance exercise metabolism and performance despite enhanced glycogen availability. The Journal of Physiology, 2021. https://doi.org/10.1113/JP280221

19. Wroble et al. Low-carbohydrate, ketogenic diet impairs anaerobic exercise performance in exercise-trained women and men: a randomized-sequence crossover trial. Journal of Sports Medicine and Physical Fitness, 2019. https://doi.org/10.23736/S0022-4707.18.08318-4

20. Noakes TD, Prins PJ, Buga A, D'Agostino DP, Volek JS, Koutnik AP. Carbohydrate ingestion on exercise metabolism and physical performance. Endocrine Reviews, 2026 (review; fat-adapted athletes show exceptional fat oxidation and equivalent performance, and carbohydrate is not an obligatory fuel). https://doi.org/10.1210/endrev/bnaf038